Skip to main content

Table 1 MIC50, MIC90, and percent susceptible, intermediate or resistant for 105 CF P. aeruginosa by reference broth microdilution and ETEST

From: Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis

Antibiotic BMD ETEST
MIC50 (µg/ml) MIC90 (µg/ml) S/I/R (%) MIC50 (µg/ml) MIC90 (µg/ml) S/I/R (%)
ATM 8 64 58/10/32 8 ≥ 256 54/11/35
FEP 8 ≥ 128 50/20/30 16 ≥ 256 32/21/47
CAZ 4 64 68/10/22 4 ≥ 256 74/6/20
CZA 2/4 8/4 90/-/10 2/4 16/4 88/-/12
C/T 1/4 4/4 92/2/6 2/4 8/4 87/6/7
CIP 2 8 27/14/59 2 ≥ 32 27/14/59
LVX 4 16 24/13/63 16 ≥ 32 20/8/72
MEM 1 32 58/6/36 1 ≥ 32 55/5/40
TZP 8/4 256/4 67/13/20 8/4 ≥ 256/4 58/15/27
TOB 2 32 63/13/24 4 64 50/20/30
  1. ATM: aztreonam; FEP: cefepime; CAZ: ceftazidime; CZA: ceftazidime–avibactam; C/T: ceftolozane–tazobactam; CIP: ciprofloxacin; LVX: levofloxacin; MEM: meropenem; TZP: piperacillin–tazobactam; TOB: tobramycin; S: susceptible; I: intermediate; R: resistant; MIC50: minimum inhibitory concentration of 50% of isolates; MIC90: minimum inhibitory concentration of 90% of isolates
\